Nearly 1 million Part D enrollees took Mounjaro, approved in 2022 for type 2 diabetes, up from 54,000 in 2022
However, since Vyvanse is a controlled substance, this option may not be available in all areas
Retatrutide has not received MHRA marketing authorisation as of mid-2025 and is not available for prescription or purchase outside approved clinical trials in the UK
Where Green Sits on the Stool Color Spectrum Green ranks among the least concerning colors a person can find in the toilet
The Medicare GLP-1 Bridge is a short-term CMS demonstration providing eligible Part D beneficiaries with access to certain GLP-1 drugs for obesity at a flat $50 monthly copay, running July 1, 2026 through December 31, 2027
The practical protocol: supplement sodium (2,000 to 3,000mg above dietary intake), potassium (1,000 to 2,000mg), and magnesium (300 to 400mg, preferably glycinate or malate form)